Ability Of Neurologix’s Gene Transfer Therapy To Quiet Abnormal Brain Activity In Parkinson’s Disease Patients Reported In PNAS

New data from the first-ever clinical trial of a novel gene therapy for advanced Parkinson’s disease demonstrate the ability of Neurologix, Inc.’s (OTCBB:NRGX) gene transfer treatment to quiet the abnormal brain activity that is correlated with the motor deficits characterizing the disease. [click link for full article]

More: continued here

Filed under: Parkinson's Disease on December 2nd, 2007